I-Mab is a biopharmaceutical company that commercializes biologics for the treatment of cancer and autoimmune disorders. The company is developing a number of products including Felzartamab, Eftansomatropin alfa, TJ107, Lemzoparlimab, Enoblituzumab, Efineptakin, TJ210, Plonmarlimab, Uliledlimab, TJ-L14B, TJ-CD4B, TJ-L1IF, and TJ-C64B. I-Mab has collaborated with several notable companies including AbbVie, Sinopharm Group, PT Kalbe Genexine Biologics, and Roche Diagnostics.